HealthEquity (HQY) – Analysts’ Weekly Ratings Updates

HealthEquity (NASDAQ: HQY) recently received a number of ratings updates from brokerages and research firms:

• 1/19/2026 – HealthEquity was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/11/2026 – HealthEquity was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 1/9/2026 – HealthEquity was downgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “sell” rating. They now have a $89.00 price target on the stock.
• 1/8/2026 – HealthEquity had its price target raised by analysts at KeyCorp from $120.00 to $125.00. They now have an “overweight” rating on the stock.
• 1/3/2026 – HealthEquity was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/8/2025 – HealthEquity is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $118.00 price target on the stock.
• 12/8/2025 – HealthEquity was upgraded by analysts at Barclays PLC to a “strong-buy” rating.
• 12/5/2025 – HealthEquity had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a $120.00 price target on the stock.
• 12/4/2025 – HealthEquity had its “market perform” rating reaffirmed by analysts at BMO Capital Markets.
• 12/4/2025 – HealthEquity was given a new $122.00 price target on by analysts at JMP Securities.
• 12/4/2025 – HealthEquity had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/4/2025 – HealthEquity had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $125.00 price target on the stock.
• 12/4/2025 – HealthEquity had its price target raised by analysts at JPMorgan Chase & Co. from $126.00 to $129.00. They now have an “overweight” rating on the stock.
• 12/4/2025 – HealthEquity had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $130.00 price target on the stock.
• 12/4/2025 – HealthEquity had its price target raised by analysts at Citizens Jmp from $117.00 to $122.00. They now have a “market outperform” rating on the stock.

Insider Activity

In other HealthEquity news, EVP Elimelech Rosner sold 10,959 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $95.45, for a total value of $1,046,036.55. Following the completion of the sale, the executive vice president directly owned 45,742 shares of the company’s stock, valued at $4,366,073.90. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Delano Ladd sold 1,500 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $94.72, for a total value of $142,080.00. Following the transaction, the executive vice president owned 73,979 shares of the company’s stock, valued at $7,007,290.88. The trade was a 1.99% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 13,959 shares of company stock worth $1,344,957. Insiders own 1.50% of the company’s stock.

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.